Inhibition effect on TGFβRII expression by TGFβRII-siRNA expression vector in hepatic stellate cells
Rong‐Quan Fu, Ju-guang Ding, Jingguo Wu, Hongliang, Qingfeng Sun
Abstract
Rong‐Quan Fu, Ju-guang Ding, Jingguo Wu, Hongliang, Qingfeng Sun
Abstract
Objective To construct transforming growth factor β receptor Ⅱ (TGFβRⅡ) siRNA expression vector, and investigate the inhibitory effect on TGFβRⅡ in hepatic stellate cells (HSC-T6) ,thus offer a preliminary study for RNAi therapy in liver fibrosis. Methods The two sites of RNAi action were selected in TGFβRⅡ cDNA through online primer design software of Ambion company. The corresponding double-stranded DNA sequence was constructed into pSilencer-U6 plasmid, which could transcribe small interference RNA, the plasmid was transfected into HSC-T6 cells with Lipofectamine 2000. The expression of TGFβRⅡ mRNA and protein were detected by reverse transcription polymerase chain reaction (RT-PCR) and western blotting. Results Expression siRNA plasmids of siRNA-a and siRNA-b that target TGFβRⅡ were successfully constructed. Compared with control group, the expression of TGFβRⅡ mRNA was reduced by 0. 89 ± 0. 06 and 0. 25 ± 0. 03 in two siRNA groups, and expression of TGFβRⅡ protein reduced to 0. 86± 0. 05 and 0. 23 ± 0. 02, respectively. TGFβRⅡ expression was inhibited at mRNA and protein levels after transfected with the siRNA-b plasmid( P 0. 05). Conclusion TGFβRⅡ-siRNA can effective inhibit expression of TGFβRⅡ in HSC-T6. Key words: Receptors, transforming growth factor beta/BI; RNA, small Interfering; Hepatocytes/ME; Liver cirrhosis/DT
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To construct transforming growth factor β receptor Ⅱ (TGFβRⅡ) siRNA expression vector, and investigate the inhibitory effect on TGFβRⅡ in hepatic stellate cells (HSC-T6) ,thus offer a preliminary study for RNAi therapy in liver fibrosis. Methods The two sites of RNAi action were selected in TGFβRⅡ cDNA through online primer design software of Ambion company. The corresponding double-stranded DNA sequence was constructed into pSilencer-U6 plasmid, which could transcribe small interference RNA, the plasmid was transfected into HSC-T6 cells with Lipofectamine 2000. The expression of TGFβRⅡ mRNA and protein were detected by reverse transcription polymerase chain reaction (RT-PCR) and western blotting. Results Expression siRNA plasmids of siRNA-a and siRNA-b that target TGFβRⅡ were successfully constructed. Compared with control group, the expression of TGFβRⅡ mRNA was reduced by 0. 89 ± 0. 06 and 0. 25 ± 0. 03 in two siRNA groups, and expression of TGFβRⅡ protein reduced to 0. 86± 0. 05 and 0. 23 ± 0. 02, respectively. TGFβRⅡ expression was inhibited at mRNA and protein levels after transfected with the siRNA-b plasmid( P 0. 05). Conclusion TGFβRⅡ-siRNA can effective inhibit expression of TGFβRⅡ in HSC-T6. Key words: Receptors, transforming growth factor beta/BI; RNA, small Interfering; Hepatocytes/ME; Liver cirrhosis/DT
Key concepts: Molecular biology, Hepatic stellate cell, Transfection, Small interfering RNA, Lipofectamine, RNA interference, Transforming growth factor, Expression vector